Aggressive adult T-cell leukemia/lymphoma (ATL) subtypes (i.e., acute and lymphomatous) are rare diseases, and the conventional management with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) has historically yielded poor outcomes. The benefit of etoposide-containing regimens (CHOEP/EPOCH) in the firs...
B. Valcárcel, Jule Vásquez, Daniel Enriquez-Vera et al.· Haematologica· 0 citations
It is concluded that access to long-term care plans is highly heterogeneous, with insufficient adaptation to the specific needs of haematological malignancy survivors treated curatively or non-curatively, and it is proposed that clinical trials should include extended follow-up, direct patient reporting, and innovative...
T. Wästerlid, B. Valcárcel, Diana Presno et al.· The Lancet Haematology· 2 citations
Background Primary ocular-adnexal non-Hodgkin lymphoma (POANHL) is a rare malignancy, but the most common tumor of the ocular adnexa. Data on real-world outcomes in Hispanic-Latino populations are limited, despite potential geographic and biologic differences. We describe the treatment and outcomes of POANHL in a Peruv...
Renato Luque-Benavides, G. A. De La Cruz Ku, B. Valcárcel et al.· PLoS ONE· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
